After Eli Lilly released trial data for its new-generation weight loss drug Retatrutide, Novo Nordisk's stock price dropped by up to 1.8%.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Eli Lilly stated that in a trial lasting one and a half years, patients who were able to tolerate the highest dose of Retatrutide experienced an average weight loss of 28.3%. Analysts noted that in terms of gastrointestinal side effects, the drug appears comparable to Novo Nordisk's Wegovy (based on the STEP-1 study); however, compared to the currently marketed GLP-1 injectables from Eli Lilly and Novo Nordisk, the dropout rate for patients on the highest dose of Retatrutide appears to be relatively high.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Crypto prices
More
Bitcoin
BTC
$83,888.79
+1.10%
Ethereum
ETH
$2,544.01
+1.59%
Tether USDt
USDT
$0.9990
+0.00%
BNB
BNB
$755.47
+0.81%
XRP
XRP
$1.42
+1.19%
USDC
USDC
$0.9999
+0.00%
Solana
SOL
$112.18
+2.04%
TRON
TRX
$0.3311
+0.04%
Hyperliquid
HYPE
$86.69
+1.40%
Zcash
ZEC
$1,280.42
+4.30%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now